TAp73 and ΔNp73 Relative Expression in Egyptian Patients with Lymphoid Neoplasms

Hamdy, Mahmoud; El-Saadany, Zainab Ali; Makhlouf, Manal Mohamed; Salama, A.E.; Ibrahim, Nihal Salah; Gad, Alaa

doi:10.5301/tj.5000506

Cited by 3 publications

(2 citation statements)

References 25 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies on lymphoma include: (1) the role of TP73 and FOXP3 in the pathogenesis of reactive lymphoid hyperplasia and diffuse B-cell lymphoma, as well as the contribution of HLA-G polymorphism to non-Hodgkin lymphoma in Egypt ( 398 – 400 ), (2) susceptibility of individuals with A/A genotype of TNF promoter (-308A/G) to non-Hodgkins lymphoma in Tunisia ( 401 ) and Egypt ( 402 ) and the identification of HLA-B*18 , DRB1*03 , DRB1*07 , and DQB1*02 as lymphoma susceptibility loci in Algerian children ( 403 ).…”

Section: Resultsmentioning

confidence: 99%

A Review of Cancer Genetics and Genomics Studies in Africa

Rotimi

Salhia

2021

Front. Oncol.

View full text Add to dashboard Cite

Cancer is the second leading cause of death globally and is projected to overtake infectious disease as the leading cause of mortality in Africa within the next two decades. Cancer is a group of genomic diseases that presents with intra- and inter-population unique phenotypes, with Black populations having the burden of morbidity and mortality for most types. At large, the prevention and treatment of cancers have been propelled by the understanding of the genetic make-up of the disease of mostly non-African populations. By the same token, there is a wide knowledge gap in understanding the underlying genetic causes of, and genomic alterations associated with, cancer among black Africans. Accordingly, we performed a review of the literature to survey existing studies on cancer genetics/genomics and curated findings pertaining to publications across multiple cancer types conducted on African populations. We used PubMed MeSH terms to retrieve the relevant publications from 1990 to December 2019. The metadata of these publications were extracted using R text mining packages: RISmed and Pubmed.mineR. The data showed that only 0.329% of cancer publications globally were on Africa, and only 0.016% were on cancer genetics/genomics from Africa. Although the most prevalent cancers in Africa are cancers of the breast, cervix, uterus, and prostate, publications representing breast, colorectal, liver, and blood cancers were the most frequent in our review. The most frequently reported cancer genes were BRCA1, BRCA2, and TP53. Next, the genes reported in the reviewed publications’ abstracts were extracted and annotated into three gene ontology classes. Genes in the cellular component class were mostly associated with cell part and organelle part, while those in biological process and molecular function classes were mainly associated with cell process, biological regulation, and binding, and catalytic activity, respectively. Overall, this review highlights the paucity of research on cancer genomics on African populations, identified gaps, and discussed the need for concerted efforts to encourage more research on cancer genomics in Africa.

show abstract

Section: Resultsmentioning

confidence: 99%

A Review of Cancer Genetics and Genomics Studies in Africa

Rotimi

Salhia

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Chemokines are the main regulators of lymphocyte and dendritic cell migration in immune homeostasis, inflammation, and infection [1]. They mediate their effects by binding to chemokine receptors which are members of a class of seven-trans-membrane G protein-coupled receptors [2].…”

Section: Introductionmentioning

confidence: 99%

CXC Chemokine Receptor Type 5 Gene Polymorphisms in a Cohort of Egyptian Patients with Diffuse Large B-Cell Lymphoma

et al. 2020

View full text Add to dashboard Cite

Background: The chemokine receptor CXCR5 is selectively expressed on B cells; it is involved in lymphocyte homing and the development of normal lymphoid tissue. Its principle ligand is CXCL13 or B lymphocyte chemoattractant. Three polymorphisms in the CXCR5 gene, rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A, have been identified. Objective: To assess the genetic polymorphisms of CXCR5 and evaluate their possible contribution to the susceptibility and response to therapy of diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Fifty DLBCL (not otherwise specified) patients and 50 control subjects were included in this study. CXCR5 genotypes were determined by PCR-RFLP. Results: Our study revealed that the CXCR5 rs148351692 C/G and rs6421571 C/T gene polymorphisms are associated with an increased risk of developing DLBCL (OR 28.57 [95% CI 8.96–96.56] and 3.45 [1.67–11.83] respectively), while CXCR5 rs78440425 G/A showed no association with the risk of lymphoma. Moreover, the double and triple combined gene polymorphisms are associated with an increased risk of developing DLBCL of approximately 120-fold and 105-fold, respectively. CXCR5 gene polymorphisms had no significant impact on disease outcome or response to therapy. Conclusions: CXCR5 gene polymorphisms could be considered a potential risk factor for the development of DLBCL.

show abstract

Clinical implications of the deregulated TP73 isoforms expression in cancer

et al. 2017

View full text Add to dashboard Cite

TP73 is a member of the TP53 family whose expression has been observed altered in most human cancers and associated with the prognosis. TP73 translates into a complex number of isoforms with both oncogenic and tumour-suppressor functions and presents a complex cross-talk with other members of the family (TP53 and TP63). In this revision, we focus on the evidence that may support TP73 variants as prognostic markers in cancer. Nowadays, most publications in this topic highlight the association between overexpression of the oncogenic variants and failure to respond to chemotherapy and/or shorter survival. In addition, we comment on the putative possibilities that the detection through a liquid biopsy of TP73 variants may provide, and finally, the significance of determining the value of the combined alteration of the TP53 family members in the clinical setting.

show abstract

TAp73 and ΔNp73 Relative Expression in Egyptian Patients with Lymphoid Neoplasms

Abstract: A considerable number of lymphoma patients lacked the expression of either or both isoforms, while all lymphoid leukemia patients expressed both isoforms. The expression pattern differences of p73 isoforms may reflect differences in the biology of these malignancies.

Cited by 3 publications

References 25 publications

A Review of Cancer Genetics and Genomics Studies in Africa

A Review of Cancer Genetics and Genomics Studies in Africa

CXC Chemokine Receptor Type 5 Gene Polymorphisms in a Cohort of Egyptian Patients with Diffuse Large B-Cell Lymphoma

Clinical implications of the deregulated TP73 isoforms expression in cancer

Contact Info

Product

Resources

About